ReviewCancers2022
Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic Significance of Up-to-Seven Criteria Versus Milan Criteria for Hepatocellular Carcinoma Patients Undergoing Resection or Locoregional Therapy: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.Hepatology international · 2024Guideline
- Should Cell Salvage Be Used in Liver Resection and Transplantation? A Systematic Review and Meta-analysis.Annals of surgery · 2023Pooled it
- A Leakage-Free Survival-Modelling Benchmark for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Nested Cross-Validation Against the Milan Criteria.Bioengineering (Basel, Switzerland) · 2026Article
- Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.Alimentary pharmacology & therapeutics · 2026Review
- Management of Satellite Lesions in Hepatocellular Carcinoma: An Updated Review.Journal of surgical oncology · 2026Review
- Access to the Liver Transplant Waitlist in Patients With HCC: A National EHR Study of Center Level Variation among 11 422 Referrals.Clinical transplantation · 2026Article
- Liver transplantation is the major determinant of ≥10-year survival in patients with hepatocellular carcinoma.Hepatology communications · 2026Article
- Liver transplantation for hepatocellular carcinoma: from patient selection and downstaging to risk stratification and post-transplant surveillance.Gastroenterology report · 2026Review
- A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction.Hepatology (Baltimore, Md.) · 2025Article
- DCAF13 Regulates Cell Proliferation and Immune Escape of Hepatocellular Carcinoma Through Activating the NF-κB Pathway.Cell biochemistry and biophysics · 2025Article
- AFP promotes cancer multidrug resistance through activating PI3K/Akt/NF-κB signaling pathway.Scientific reports · 2025Article
- Review
- Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions.Discover oncology · 2025Review
- Transplantation of Patients with Hepatocellular Carcinoma Through Increased Utilization of Machine Perfusion Technology.Transplantation direct · 2025Article
- Efficacy of magnetic resonance imaging in managing glycogen storage disease.Orphanet journal of rare diseases · 2025Article
- Deep learning for hepatocellular carcinoma recurrence before and after liver transplantation: a multicenter cohort study.Scientific reports · 2025Article
- A novel phosphodiesterase target as a therapeutic approach: inhibiting DEN-induced hepatocellular carcinoma progression.EXCLI journal · 2025Review
- Long-Term Prognostic Value of AFP and PIVKA-II in HCC After Living Donor Liver Transplantation: A Single-Center Retrospective Study.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Are Ki-67 and Procalcitonin Expression Levels Useful in Predicting the Biological Behavior of Hepatocellular Carcinoma After Liver Transplantation?Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the third highest cause of cancer-related mortality, and liver transplantation is the ideal treatment for this disease. The Milan criteria provided the opportunity for HCC patients to undergo LT with favorable outcomes and have been the international gold standard and benchmark. With the accumulation of data, however, the Milan criteria are not regarded as too restrictive. After the implementation of the Milan criteria, many extended criteria have been proposed, which increases the limitations regarding the morphological tumor burden, and incorporates the tumor's biological behavior using surrogate markers. The paradigm for the patient selection for LT appears to be shifting from morphologic criteria to a combination of biologic, histologic, and morphologic criteria, and to the establishment of a model for predicting post-transplant recurrence and outcomes. This review article aims to characterize the various patient selection criteria for LT, with reference to several surrogate markers for the biological behavior of HCC (e.g., AFP, PIVKA-II, NLR, 18F-FDG PET/CT, liquid biopsy), and the response to locoregional therapy. Furthermore, the allocation rules in each country and the present evidence on the role of down-staging large tumors are addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.